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1. Introduction
  Lung cancer is a kind of cancer with the highest 
mortality rate around the world. According to clinical 
manifestations, lung cancer can be categorized into non-
small cell lung cancer and small cell lung cancer. Greatly 
different from epithelial cancer (such as adenocarcinoma 
and squamous cell carcinoma) in biomorphology and 
development, small cell lung cancer is highly malignant, 
spreads rapidly in the early period after onset, and is very 
sensitive to chemotherapy and radiotherapy. Chemotherapy, 
radiotherapy, surgery and biotherapy are the major 
treatment modalities of small cell lung cancer. The key step 
of small cell lung cancer treatment is to know cell changes 
in cancer tissue. 5-Aza-2’-deoxycitydine (DAC), a DNA 
methyltransferase inhibitor, has been used to deteriorate 
hypermethylated gene expression, inhibit the growth 
of various cells[1-3], accelerate tumor necrosis factor-
mediated malignant melanoma cell apoptosis and promote 
the expression of quiescent gene MAGE-1[4-6]. In addition, 
DAC can inhibit DNA and protein synthesis in tumor 
cells by inhibiting intracellular dihydrofolate reductase 
expression[7,8]. This can stop the growth of cancer cells 
and even lead to cellular death. This study investigated 
the effects of DAC on the proliferation, apoptosis and lipid 
peroxidation of human lung adenocarcinoma epithelial 
cell line A549 and the underlying mechanisms in order to 
provide theoretical evidence for clinical use of DAC.  
  
2. Materials and methods
2.1. Materials 
2.1.1. Cells and their culture 
   Human lung adenocarcinoma epithelial cell line A549 
(China Center for Type Culture Collection, Zhejiang 
University, China) was cultured with DMEM (Gibco, 
Objective: To explore effect of 5-AZn-2 '-deoxycytidine on proliferation of human lung 
adenocarcinoma cell line A549 in vitro. Methods: Superoxide dismutase (SOD) activity was 
measured by hydroxylamine colorimetric method. Inhibition effect of 5-AZn-2’ deoxycytidylic 
acid at different concentration and different time on growth of A549 cell was determined by MTT 
assay. Methylene dioxyamphetamine (MDA) was measured by thiobarbituric acid colorimetric 
method. Effect of 5-AZn-2’ deoxycytidylic acid on apoptosis of A549 cell was determined by 
Hoechst 33258 dyeing detection. Results: 5-AZn-2' deoxycytidylic acid had significant inhibition 
effect on proliferation of A549 cells in vitro, and the inhibition was notably dependent on time 
and dosage during 48-72 h; SOD level was significantly lower than those of control group (P<0.05, 
P<0.01), MDA level was significantly higher than those in the control group (P<0.05, P<0.01). 
A549 cells began to be in apoptosis after using 5-AZn-2' deoxycytidylic acid. Conclusions: 5- 
AZn-2' deoxycytidylic acid has significant inhibition effect on growth of A549 cell, and can lead 
the change of lipid peroxidation. It indicates that the mechanism has relationship with A549 cell 
cycle tissue and induction factor of apoptosis.
Na Li et al./Asian Pacific Journal of Tropical Medicine (2013)982-985 983
Carlsbad, CA, USA) containing 10% fetal bovine serum 
(Sijiqing, Zhejiang Tianhang Biological Technology Co., 
Ltd., China) in an incubator at 37 曟, 5% CO2 with saturated 
humidity and then digested with 0.25% trypsin for passage. 
2.1.2. Drugs and reagents
  DAC (Shanghai Hualian Pharmaceutical Co., Ltd., Shanghai, 
China) was prepared into 1 mol/L solution with physiological 
saline and diluted into the required concentrations with 
DMEM when use. MTT solution was purchased from Huamei 
Bioengineering Co., Ltd., China. Hochest33258 and dimethyl 
sulfoxide (DMSO) were purchased from Sigma, St. Louis, MO, 
USA. 
2.2. Methods
2.2.1. Cell line and cell culture 
  Human lung adenocarcinoma epithelial cell line A549 
was cultured with RPMI-1640 culture medium containing 
10% fetal bovine serum, 100 U/mL penicillin and 100 U/mL 
streptomycin at 37 曟, 5%CO2 with saturated humidity. When 
cells reached 80% confluence, they were digested with 0.25% 
trypsin for passage.
2.2.2. DAC preparation
  100 mmol/L DAC stock solution was prepared with a small 
amount of DMSO by applying an ultrasonic wave. Prior to 
experiment, DAC was diluted to the required concentration 
(DMSO final concentration < 0.1%) with RPMI-1640 culture 
medium. 
2.2.3. MTT assay
  Human lung adenocarcinoma epithelial cell line A549 at the 
log phase of growth were seeded into a 96-well plate, 2暳10
3 
cells/well. After 12 h of culture, these cells were incubated 
with DMSO (control group) or different concentrations 
(0, 0.25, 0.5, 2.5, 12.5 毺mol/L) of DAC solution (DAC 
groups) at 37 曟 and 5% CO2 under saturated humidity for 
12, 24, 48 and 72 h. Five parallel wells were designated 
for each group. After removal of supernatant, 20 毺L 
MTT solution (5 g/L) was added to each well and A549 cells 
were incubated at 37 曟 for 4 more hours. Supernatant was 
removed, then 150 毺L DMSO was added to each well and 
A549 cells were oscillated for 10 min. Absorbance at 490 nm
was determined through the use of ELISA reader. Each 
experiment was repeated three times. Cell growth curve 
was drawn and cell growth inhibitory rate was calculated 
according to the formula: Cell growth inhibitory rate (%) = (1- 
absorbance in the DAC group/absorbance rate in the control 
group) 暳100%. 
2.2.4. Cell morphology and cell apoptosis rate
  Cell apoptosis in each group was detected using Hoechst 
33258 staining. A549 cells (2暳10
4/well) were seeded in each 
well in which a piece of sterile coverslip was pre-placed and 
five parallel wells were used for each group. When adhering 
to culture plate, A549 cells were treated with different 
concentrations of DAC (0, 0.25, 0.5, 2.5, 12.5 毺mol/L) or 
DMSO for 24, 48, 72 and 96 h. Culture medium was removed, 
then A549 cells were collected, washed and evenly smeared. 
After natural drying, the cells were treated with 0.05 mg/L 
Hoechst33258 and 0.1 mg/L calcium- and magnesium-
free thiomersal for 40 min. After mounting, the cells were 
observed under the fluorescence microscope, photographed 
and counted. 
2.2.5. Detection of superoxide dismutase (SOD) and 
malondialdehyde (MDA) activities in A549 cells 
  In strict accordance with the instructions of reagent 
kits provided by Nanjing Juli Biomedical Engineering 
Institute (Nanjing, China), SOD activity was measured 
by hydroxylamine chromatometry and MDA activity by 
thiobarbituric acid-reactive-substances assay. 
2.3. Statistical analysis
 All data were expressed as mean暲SD and statistically 
processed with SPSS16.0 software (SPSS, Chicago, IL, USA). t 
test was used. A level of P<0.05 was considered statistically 
significant. 
3. Results
3.1. Effects of DAC on A549 cell proliferation 
  
  DAC at a concentration of 0.5, 2.5 and 12.5 毺mol/L 
significantly inhibited the growth of A549 cells in a time- 























Figure 1. Time and dose-dependent effects of different concentrations 
of DAC on A549 cell proliferation. 
3.2. Effects of DAC on SOD and MDA activities in A549 cells 
  The SOD activity in the DAC (0.5, 2.5 and 12.5 毺mol/L) 
groups was significantly, dose-dependently lower compared 
with the control group (P<0.05, P<0.01). The MDA activity in 
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the DAC (0.5, 2.5 and 12.5 毺mol/L) groups was significantly, 
dose-dependently higher compared with the control group 
(P<0.05, P<0.01) (Table 1).  
Table 1
Effects of DAC on SOD and MDA activities in the A549 cells (Mean暲SD, 
n=10).
Group SOD (U/mg) MDA (nmol/mg)
Control 72.23暲2.40 24.23暲3.20
DAC 0.25 毺mol/L 69.26暲2.70 32.26暲3.20
DAC 0.5 毺mol/L 56.42暲4.40a 37.43暲5.20a
DAC 2.5 毺mol/L 52.64暲2.50a 45.52暲4.30a
DAC 12.5 毺mol/L 49.45暲3.20b 57.58暲3.40b
a: P<0.05, b: P<0.01, vs. control group. 
3.3. Effects of DAC on A549 cell apoptosis rate and 
morphology 
  Five visual fields were randomly selected under high-fold 
magnification for counting total cells and apoptotic cells. 
Cell apoptosis rate was calculated according to the formula: 
cell apoptosis rate = number of apoptotic cells/total cell 
number暳100%. Cell apoptosis rate reached its peak in the 
DAC (0.5, 2.5, 12.5 毺mol/L) groups at 48 and 72 h, which was 
significantly higher compared to the control group (P<0.05, 
P<0.01) (Table 2). Hoechst33258 fluorescent staining showed 
that after 72 h of DAC treatment, cell fluorescent staining 
was light and even and no apoptotic cells were observed 
in the control group (Figure 2A); cell apoptosis signs 
including karyopyknosis, chromatic agglutination, vacuole 
and apoptotic body were observed in the DAC (0.5, 2.5 and 
12.5 毺mol/L) groups (Figures 2B-D), indicating that DAC 
induced apoptosis of A549 cells.  
A B
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Figure 2. Effects of DAC on A549 cell apoptosis rate and morphology.
A: Cell morphology of A549 cells in the control group (暳200); B: 
Morphology of apoptotic A549 cells induced by 0.5 毺mol/L DAC for 72 
h (暳200); C: Morphology of apoptotic A549 cells induced by 2.5 毺mol/
L DAC for 72 h (暳200); D: Morphology of apoptotic A549 cells induced 
by 12.5 毺mol/L DAC for 72 h (暳200).
Table 2
Effects of DAC on A549 cell apoptosis rate (n = 5, %)
Group Cell apoptosis rate (%)
24 h 48 h 72 h
Control   2.23暲0.52   2.60暲0.26   2.50暲0.45
DAC 0.25 毺mol/L   6.30暲1.64   6.92暲3.23 22.36暲3.44a
DAC 0.5 毺mol/L 11.50暲2.32a 24.35暲6.26b 29.36暲5.34b
DAC 2.5 毺mol/L 13.50暲3.84a 29.87暲5.84b 36.54暲6.34b
DAC 12.5 毺mol/L 16.20暲2.53a 34.83暲7.44b 42.52暲8.26b
a: P<0.05, b: P<0.01, vs. control group.
4. Discussion
   The development and apoptosis of tumor cells result from 
coaction of many proteins and proteases in the human body. 
Cell apoptosis is the process of programmed cell death and 
controlled by genes[9,10]. This process can help protect the 
environment in the human body because only programmed 
cell growing and apoptosis can balance and stabilize the 
environment in the human body. This principle is used 
by gene therapy, a treatment method of tumor, which uses 
drugs (such as 5-fluorouracil, cisplatin, mitomycin, DAC 
and Chinese herbal medicine) that can lead to programmed 
death of tumor cells. Abnormal cell apoptosis can give rise 
to tumor formation, abnormal immunological function and 
changes in cell biological characteristics[11-14]. Results 
from this study showed that DAC inhibited the proliferation 
of A549 cells as confirmed by MTT assay; that is to say, 
DAC promoted the death of tumor cells and inhibited the 
proliferation of tumor cells.  
  The effects of DAC on A549 cells are greatly different 
at different doses and for different periods of time, so 
much care needs to be taken over the dose and periods of 
time[15,16]. In this study, we also observed the morphology 
of DAC-treated A549 cells and found that the cancer cells 
turned from spreading status before DAC treatment to 
round appearance with apoptotic characteristics including 
cell shrinkage, nuclear chromatin concentration, nuclear 
fragmentation, budding and apoptotic body formation after 
DAC treatment. Cell apoptosis rate reached its peak after 
DAC (0.5, 2.5 and 12.5 毺mol/L) treatment for 48 and 72 h, 
respectively. 
  Under normal circumstance, the generation and removal 
of reactive oxygen species are dynamically balanced. 
When the organisms are stimulated by some abnormal 
physiochemical factors, a large amount of reactive oxygen 
species will be produced, which destroy the balance of 
oxidation-reduction, and excessive reactive oxygen species 
will cause lipid peroxidation[17-19]. MDA is the end-product 
of lipid peroxidation. Increased MDA activity indicates the 
unbalance between DAC oxidation and anti-oxidation[20,21]. 
Results from this study showed that MDA activity increased 
dose-dependently in DAC-treated A549 cells. SOD activity 
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decreased in DAC-treated A549 cells possibly because DAC 
inactivated SOD by binding SOD dynamic sites, especially 
sulfhydryl-containing protein groups. This inevitably 
decreases the ability of organism to remove free radicals and 
increases intracellular oxidation, thereby causing oxidative 
damage[22-25]. Results from this study suggest that DAC 
anti-cancer drugs are effective in the treatment of lung 
cancer by causing lung cancer cell apoptosis and changes 
in lipid peroxidation, providing experimental evidence for 
their clinical application. The underlying mechanism needs 
further investigation. 
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